Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
$1.20
+9.1%
$1.16
$7.80
$12.38
$20.70MN/A41,322 shs500,328 shs
Mannatech, Incorporated stock logo
MTEX
Mannatech
$8.70
-4.4%
$9.79
$7.00
$16.49
$16.53M0.896,035 shs728 shs
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$0.43
-2.4%
$0.31
$0.24
$1.47
$30.36M0.13447,216 shs295,412 shs
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
$9.03
-1.1%
$8.21
$6.15
$905.52
$7.50M1.4103,893 shs13,422 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
+6.19%+14.29%-4.76%-1.64%-66.67%
Mannatech, Incorporated stock logo
MTEX
Mannatech
+2.44%-5.38%-17.11%+3.67%+18.83%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
+1.72%+32.34%+32.07%+71.53%-47.29%
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
-1.30%+10.13%+21.73%-18.20%-99.96%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
Mannatech, Incorporated stock logo
MTEX
Mannatech
0.2897 of 5 stars
0.03.00.00.00.61.70.0
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
4.2156 of 5 stars
3.63.00.04.60.62.50.6
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
2.0603 of 5 stars
3.54.00.00.00.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
0.00
N/AN/AN/A
Mannatech, Incorporated stock logo
MTEX
Mannatech
0.00
N/AN/AN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
3.20
Buy$3.13614.45% Upside
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
3.00
Buy$280.002,966.81% Upside

Current Analyst Ratings Breakdown

Latest RNAZ, JATT, OVID, and MTEX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$2.00 ➝ $1.50
4/24/2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/16/2025
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$560.00 ➝ $280.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/A$0.04 per share27.08($0.53) per shareN/A
Mannatech, Incorporated stock logo
MTEX
Mannatech
$117.87M0.14$2.19 per share3.94$4.57 per share1.89
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$570K54.57N/AN/A$0.96 per share0.46
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/AN/AN/AN/A($54.96) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
$6.85MN/A0.00N/AN/A-49.58%2.84%N/A
Mannatech, Incorporated stock logo
MTEX
Mannatech
$2.49M-$0.10N/AN/A-0.19%-2.56%-0.57%8/12/2025 (Estimated)
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$26.43M-$0.35N/AN/AN/A-4,562.23%-34.17%-25.34%8/12/2025 (Estimated)
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
-$16.75MN/A0.00N/AN/AN/A-578.88%-222.61%N/A

Latest RNAZ, JATT, OVID, and MTEX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q4 2024
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
-$2.00-$0.60+$1.40-$2.51$0.30 millionN/A
5/13/2025Q1 2025
Mannatech, Incorporated stock logo
MTEX
Mannatech
N/A-$0.80N/A-$0.80N/A$26.56 million
5/13/2025Q1 2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$0.14-$0.14N/A-$0.14$0.03 million$0.13 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/AN/AN/AN/AN/A
Mannatech, Incorporated stock logo
MTEX
Mannatech
N/AN/AN/AN/AN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
N/AN/AN/AN/AN/A
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
N/A
0.15
0.15
Mannatech, Incorporated stock logo
MTEX
Mannatech
0.46
1.18
0.65
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
0.22
4.93
4.93
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/A
5.20
5.20

Institutional Ownership

CompanyInstitutional Ownership
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
47.97%
Mannatech, Incorporated stock logo
MTEX
Mannatech
12.98%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
72.24%
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
20.00%
Mannatech, Incorporated stock logo
MTEX
Mannatech
41.50%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
13.10%
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
0.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
JATT Acquisition Corp stock logo
JATT
JATT Acquisition
317.25 million13.80 millionNot Optionable
Mannatech, Incorporated stock logo
MTEX
Mannatech
2501.90 million1.11 millionNot Optionable
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
6071.11 million61.80 millionOptionable
TransCode Therapeutics Inc. stock logo
RNAZ
TransCode Therapeutics
9830,000832,000Not Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
JATT Acquisition stock logo

JATT Acquisition NYSE:JATT

$1.20 +0.10 (+9.09%)
As of 07/8/2025

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.

Mannatech stock logo

Mannatech NASDAQ:MTEX

$8.70 -0.40 (-4.40%)
As of 12:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.

Ovid Therapeutics stock logo

Ovid Therapeutics NASDAQ:OVID

$0.43 -0.01 (-2.38%)
As of 12:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

TransCode Therapeutics stock logo

TransCode Therapeutics NASDAQ:RNAZ

$9.03 -0.10 (-1.10%)
As of 12:24 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.